4997
Riferimenti bibliografici
4998 4999
1, n.d. COT STATEMENT ON THE TOLE RABLE DAILY INTAKE FOR PERFLUOROOCTANE 5000
SULFONATE [WWW Document]. URL 5001
http://cot.food.gov.uk/sites/default/files/cot/cotstatementpfos200609.pdf (accessed 5002
9.22.14).
5003
15, B.P., 2006, Pm, 8:40, n.d. Teflon Chemical A Likely Carcinogen [WWW Document]. URL 5004
http://www.cbsnews.com/news/teflon-‐chemical-‐a-‐likely-‐carcinogen/2/ (accessed 5005
9.25.14).
5006
2010/2015 PFOA Stewardship Program| PFOA and Fluorinated Telomers | OPPT | 5007
OPPTS| US EPA [WWW Document], n.d. URL 5008
http://www.epa.gov/oppt/pfoa/pubs/stewardship// (accessed 7.6.14).
5009
Abbott, B.D., 2009. Review of the expression of peroxisome proliferator-‐activated 5010
receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent 5011
and human development. Reprod. Toxicol. Elmsford N 27, 246–257.
5012
doi:10.1016/j.reprotox.2008.10.001 5013
Acqua contaminata, l’UE indaga sulle misure prese dalle autorità venete | Andrea Zanoni 5014
[WWW Document], n.d. URL http://www.andreazanoni.it/it/news/comunicati-‐
5015
stampa/acqua-‐contaminata-‐l-‐ue-‐indaga-‐sulle-‐misure-‐prese-‐dalle-‐autorita-‐
5016
venete.html%20 (accessed 8.23.14).
5017
Agency, F.S., n.d. Members of COT [WWW Document]. URL 5018
http://cot.food.gov.uk/membership/members (accessed 9.25.14).
5019
Ahrens, L., Bundschuh, M., 2014. Fate and effects of poly-‐ and perfluoroalkyl substances in 5020
the aquatic environment: A review. Environ. Toxicol. Chem. SETAC. doi:10.1002/etc.2663 5021
Ahrens, L., Norström, K., Viktor, T., Cousins, A.P., Josefsson, S., 2014. Stockholm Arlanda 5022
Airport as a source of per-‐ and polyfluoroalkyl substances to water, sediment and fish.
5023
Chemosphere. doi:10.1016/j.chemosphere.2014.03.136 5024
Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., 5025
Fruchart, J.-‐C., James, W.P.T., Loria, C.M., Smith, S.C., International Diabetes Federation 5026
Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, 5027
American Heart Association, World Heart Federation, International Atherosclerosis 5028
Society, International Association for the Study of Obesity, 2009. Harmonizing the 5029
metabolic syndrome: a joint interim statement of the International Diabetes Federation 5030
Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;
5031
American Heart Association; World Heart Federation; International Atherosclerosis 5032
Society; and International Association for the Study of Obesity. Circulation 120, 1640–
5033
1645. doi:10.1161/CIRCULATIONAHA.109.192644 5034
Apelberg, B.J., Goldman, L.R., Calafat, A.M., Herbstman, J.B., Kuklenyik, Z., Heidler, J., 5035
Needham, L.L., Halden, R.U., Witter, F.R., 2007. Determinants of fetal exposure to 5036
polyfluoroalkyl compounds in Baltimore, Maryland. Environ. Sci. Technol. 41, 3891–3897.
5037
Arpav_-‐_relazione_11_Luglio_2013.pdf, n.d.
5038
Atlante di mortalità regionale. Anni 1981-‐2000. Giunta regionale del Veneto, n.d.
5039
Audet-‐Delage, Y., Ouellet, N., Dallaire, R., Dewailly, E., Ayotte, P., 2013. Persistent organic 5040
pollutants and transthyretin-‐bound thyroxin in plasma of Inuit women of childbearing 5041
age. Environ. Sci. Technol. 47, 13086–13092. doi:10.1021/es4027634 5042
Aumento dei linfomi a Vicenza, Prc solidale con il dottor Cordiano » VicenzaPiù [WWW 5043
Document], n.d. URL http://www.vicenzapiu.com/leggi/aumento-‐dei-‐linfomi-‐a-‐vicenza-‐
5044
prc-‐solidale-‐con-‐il-‐dottor-‐cordiano (accessed 8.23.14).
5045
Barry, V., Winquist, A., Steenland, K., 2013. Perfluorooctanoic acid (PFOA) exposures and 5046
incident cancers among adults living near a chemical plant. Environ. Health Perspect. 121, 5047
1313–1318. doi:10.1289/ehp.1306615 5048
Basic Information | Risk Assessment Portal | US EPA [WWW Document], n.d. URL 5049
http://epa.gov/riskassessment/basicinformation.htm#risk (accessed 9.9.14).
5050
Bellinger, D.C., 2012. Comparing the population neurodevelopmental burdens associated 5051
with children’s exposures to environmental chemicals and other risk factors.
5052
Neurotoxicology 33, 641–643. doi:10.1016/j.neuro.2012.04.003 5053
Benbrahim-‐Tallaa, L., Lauby-‐Secretan, B., Loomis, D., Guyton, K.Z., Grosse, Y., El Ghissassi, 5054
F., Bouvard, V., Guha, N., Mattock, H., Straif, K., International Agency for Research on 5055
Cancer Monograph Working Group, 2014. Carcinogenicity of perfluorooctanoic acid, 5056
tetrafluoroethylene, dichloromethane, 1,2-‐dichloropropane, and 1,3-‐propane sultone.
5057
Lancet Oncol. 15, 924–925.
5058
Benford, D., de Boer, J., Carere, A., di Domenico, A., Johansson, N., Schrenk, D., Schoeters, G., 5059
de Voogt, P., Dellatte, E., 2008. Opinion of the Scientific Panel on Contaminants in the Food 5060
chain on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts.
5061
EFSA J. 1–131.
5062
Bernal, J., 2007. Thyroid hormone receptors in brain development and function. Nat. Clin.
5063
Pract. Endocrinol. Metab. 3, 249–259. doi:10.1038/ncpendmet0424 5064
Bernstein, I.M., Horbar, J.D., Badger, G.J., Ohlsson, A., Golan, A., 2000. Morbidity and 5065
mortality among very-‐low-‐birth-‐weight neonates with intrauterine growth restriction.
5066
The Vermont Oxford Network. Am. J. Obstet. Gynecol. 182, 198–206.
5067
Biegel, L.B., Hurtt, M.E., Frame, S.R., O’Connor, J.C., Cook, J.C., 2001. Mechanisms of 5068
extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci.
5069
Off. J. Soc. Toxicol. 60, 44–55.
5070
Biegel, L.B., Liu, R.C., Hurtt, M.E., Cook, J.C., 1995. Effects of ammonium perfluorooctanoate 5071
on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol. Appl. Pharmacol. 134, 5072
18–25. doi:10.1006/taap.1995.1164 5073
Bjork, J.A., Butenhoff, J.L., Wallace, K.B., 2011. Multiplicity of nuclear receptor activation 5074
by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 288, 8–17.
5075
doi:10.1016/j.tox.2011.06.012 5076
Bonefeld-‐Jorgensen, E.C., Long, M., Bossi, R., Ayotte, P., Asmund, G., Krüger, T., Ghisari, M., 5077
Mulvad, G., Kern, P., Nzulumiki, P., Dewailly, E., 2011. Perfluorinated compounds are 5078
related to breast cancer risk in greenlandic inuit: A case control study. Environ. Health 10, 5079
88. doi:10.1186/1476-‐069X-‐10-‐88 5080
Bookstaff, R.C., Moore, R.W., Ingall, G.B., Peterson, R.E., 1990. Androgenic deficiency in 5081
male rats treated with perfluorodecanoic acid. Toxicol. Appl. Pharmacol. 104, 322–333.
5082
Botero, D., Lifshitz, F., 1999. Intrauterine growth retardation and long-‐term effects on 5083
growth. Curr. Opin. Pediatr. 11, 340–347.
5084
Bots, M.L., Hoes, A.W., Koudstaal, P.J., Hofman, A., Grobbee, D.E., 1997. Common carotid 5085
intima-‐media thickness and risk of stroke and myocardial infarction: the Rotterdam 5086
Study. Circulation 96, 1432–1437.
5087
Brandsma, S.H., Smithwick, M., Solomon, K., Small, J., de Boer, J., Muir, D.C.G., 2011. Dietary 5088
exposure of rainbow trout to 8:2 and 10:2 fluorotelomer alcohols and 5089
perfluorooctanesulfonamide: Uptake, transformation and elimination. Chemosphere 82, 5090
253–258. doi:10.1016/j.chemosphere.2010.09.050 5091
Brieger, A., Bienefeld, N., Hasan, R., Goerlich, R., Haase, H., 2011. Impact of 5092
perfluorooctanesulfonate and perfluorooctanoic acid on human peripheral leukocytes.
5093
Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 25, 960–968. doi:10.1016/j.tiv.2011.03.005 5094
Brodsky, D., Christou, H., 2004. Current concepts in intrauterine growth restriction. J.
5095
Intensive Care Med. 19, 307–319. doi:10.1177/0885066604269663 5096
Buck Louis, G.M., Chen, Z., Schisterman, E.F., Kim, S., Sweeney, A.M., Sundaram, R., Lynch, 5097
C.D., Gore-‐Langton, R.E., Barr, D.B., 2014. Perfluorochemicals and Human Semen Quality:
5098
The LIFE Study. Environ. Health Perspect. doi:10.1289/ehp.1307621 5099
Buck, R.C., Franklin, J., Berger, U., Conder, J.M., Cousins, I.T., de Voogt, P., Jensen, A.A., 5100
Kannan, K., Mabury, S.A., van Leeuwen, S.P., 2011. Perfluoroalkyl and Polyfluoroalkyl 5101
Substances in the Environment: Terminology, Classification, and Origins. Integr. Environ.
5102
Assess. Manag. 7, 513–541. doi:10.1002/ieam.258 5103
Bukowski, R., 2004. Fetal growth potential and pregnancy outcome. Semin. Perinatol. 28, 5104
51–58.
5105
Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., 5106
Lieder, P., Olsen, G., Thomford, P., 2002. Toxicity of Ammonium Perfluorooctanoate in 5107
Male Cynomolgus Monkeys after Oral Dosing for 6 Months. Toxicol. Sci. 69, 244–257.
5108
doi:10.1093/toxsci/69.1.244 5109
Butenhoff, J.L., Chang, S.-‐C., Olsen, G.W., Thomford, P.J., 2012a. Chronic dietary toxicity and 5110
carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats.
5111
Toxicology 293, 1–15. doi:10.1016/j.tox.2012.01.003 5112
Butenhoff, J.L., Kennedy, G.L., Chang, S.-‐C., Olsen, G.W., 2012b. Chronic dietary toxicity and 5113
carcinogenicity study with ammonium perfluorooctanoate in Sprague-‐Dawley rats.
5114
Toxicology 298, 1–13. doi:10.1016/j.tox.2012.04.001 5115
Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O’Connor, J.C., York, R.G., 2004. The 5116
reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 5117
196, 95–116. doi:10.1016/j.tox.2003.11.005 5118
Butenhoff, J.L., Kennedy, G.L., Hinderliter, P.M., Lieder, P.H., Jung, R., Hansen, K.J., Gorman, 5119
G.S., Noker, P.E., Thomford, P.J., 2004. Pharmacokinetics of perfluorooctanoate in 5120
cynomolgus monkeys. Toxicol. Sci. Off. J. Soc. Toxicol. 82, 394–406.
5121
doi:10.1093/toxsci/kfh302 5122
Butt, C.M., Berger, U., Bossi, R., Tomy, G.T., 2010a. Levels and trends of poly-‐ and 5123
perfluorinated compounds in the arctic environment. Sci. Total Environ. 408, 2936–2965.
5124
doi:10.1016/j.scitotenv.2010.03.015 5125
Butt, C.M., Muir, D.C.G., Mabury, S.A., 2010b. Elucidating the pathways of poly-‐ and 5126
perfluorinated acid formation in rainbow trout. Environ. Sci. Technol. 44, 4973–4980.
5127
doi:10.1021/es100702a 5128
Butt, C.M., Muir, D.C.G., Mabury, S.A., 2014. Biotransformation pathways of fluorotelomer-‐
5129
based polyfluoroalkyl substances: a review. Environ. Toxicol. Chem. SETAC 33, 243–267.
5130
doi:10.1002/etc.2407 5131
C-‐8 Investigation Reports [WWW Document], n.d. URL 5132
http://www.dep.wv.gov/WWE/watershed/wqmonitoring/Pages/C-‐8.aspx (accessed 5133
8.23.14).
5134
C8 Science Panel Website [WWW Document], n.d. URL 5135
http://www.c8sciencepanel.org/c8health.html (accessed 7.30.14).
5136
Calafat, A.M., Kuklenyik, Z., Caudill, S.P., Reidy, J.A., Needham, L.L., 2006.
5137
Perfluorochemicals in pooled serum samples from United States residents in 2001 and 5138
2002. Environ. Sci. Technol. 40, 2128–2134.
5139
Casals-‐Casas, C., Desvergne, B., 2011. Endocrine disruptors: from endocrine to metabolic 5140
disruption. Annu. Rev. Physiol. 73, 135–162. doi:10.1146/annurev-‐physiol-‐012110-‐
5141
142200 5142
Caserta, D., Ciardo, F., Bordi, G., Guerranti, C., Fanello, E., Perra, G., Borghini, F., La Rocca, 5143
C., Tait, S., Bergamasco, B., Stecca, L., Marci, R., Lo Monte, G., Soave, I., Focardi, S., 5144
Mantovani, A., Moscarini, M., 2013. Correlation of Endocrine Disrupting Chemicals Serum 5145
Levels and White Blood Cells Gene Expression of Nuclear Receptors in a Population of 5146
Infertile Women. Int. J. Endocrinol. 2013. doi:10.1155/2013/510703 5147
Cassone, C.G., Taylor, J.J., O’Brien, J.M., Williams, A., Yauk, C.L., Crump, D., Kennedy, S.W., 5148
2012a. Transcriptional profiles in the cerebral hemisphere of chicken embryos following 5149
in ovo perfluorohexane sulfonate exposure. Toxicol. Sci. Off. J. Soc. Toxicol. 129, 380–391.
5150
doi:10.1093/toxsci/kfs219 5151
Cassone, C.G., Vongphachan, V., Chiu, S., Williams, K.L., Letcher, R.J., Pelletier, E., Crump, D., 5152
Kennedy, S.W., 2012b. In ovo effects of perfluorohexane sulfonate and 5153
perfluorohexanoate on pipping success, development, mRNA expression, and thyroid 5154
hormone levels in chicken embryos. Toxicol. Sci. Off. J. Soc. Toxicol. 127, 216–224.
5155
doi:10.1093/toxsci/kfs072 5156
CDC Centers for Disease Control and Prevention, n.d. Fourth National Report on Human 5157
Exposure to Environmental Chemicals Updated Tables, August, 2014 [WWW Document].
5158
URL 5159
http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Aug2014.pdf 5160
(accessed 9.9.14).
5161
Chang, E.T., Adami, H.-‐O., Boffetta, P., Cole, P., Starr, T.B., Mandel, J.S., 2014. A critical 5162
review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in 5163
humans. Crit. Rev. Toxicol. 44, 1–81. doi:10.3109/10408444.2014.905767 5164
Chang, S.-‐C., Ehresman, D.J., Bjork, J.A., Wallace, K.B., Parker, G.A., Stump, D.G., Butenhoff, 5165
J.L., 2009. Gestational and lactational exposure to potassium perfluorooctanesulfonate 5166
(K+PFOS) in rats: toxicokinetics, thyroid hormone status, and related gene expression.
5167
Reprod. Toxicol. Elmsford N 27, 387–399. doi:10.1016/j.reprotox.2009.01.005 5168
Chang, S.-‐C., Noker, P.E., Gorman, G.S., Gibson, S.J., Hart, J.A., Ehresman, D.J., Butenhoff, J.L., 5169
2012. Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, 5170
and monkeys. Reprod. Toxicol. Elmsford N 33, 428–440.
5171
doi:10.1016/j.reprotox.2011.07.002 5172
Che acqua si beve nella Provincia di Vicenza? | Gruppo d’Intervento Giuridico onlus, n.d.
5173
CHEMICALS, P.O.P., 2006. SLIPPING AWAY.
5174
Cheng, J., Fujimura, M., Zhao, W., Wang, W., 2013. Neurobehavioral effects, c-‐Fos/Jun 5175
expression and tissue distribution in rat offspring prenatally co-‐exposed to MeHg and 5176
PFOA: PFOA impairs Hg retention. Chemosphere 91, 758–764.
5177
doi:10.1016/j.chemosphere.2013.02.016 5178
Chen, M.-‐H., Ha, E.-‐H., Wen, T.-‐W., Su, Y.-‐N., Lien, G.-‐W., Chen, C.-‐Y., Chen, P.-‐C., Hsieh, W.-‐S., 5179
2012. Perfluorinated compounds in umbilical cord blood and adverse birth outcomes.
5180
PloS One 7, e42474. doi:10.1371/journal.pone.0042474 5181
Chen, Y.-‐M., Guo, L.-‐H., 2009. Fluorescence study on site-‐specific binding of perfluoroalkyl 5182
acids to human serum albumin. Arch. Toxicol. 83, 255–261. doi:10.1007/s00204-‐008-‐
5183
0359-‐x 5184
Chien, K.-‐L., Su, T.-‐C., Jeng, J.-‐S., Hsu, H.-‐C., Chang, W.-‐T., Chen, M.-‐F., Lee, Y.-‐T., Hu, F.B., 5185
2008. Carotid artery intima-‐media thickness, carotid plaque and coronary heart disease 5186
and stroke in Chinese. PloS One 3, e3435. doi:10.1371/journal.pone.0003435 5187
Chinetti, G., Fruchart, J.C., Staels, B., 2001. Peroxisome proliferator-‐activated receptors 5188
(PPARs): nuclear receptors with functions in the vascular wall. Z. Für Kardiologie 90 5189
Suppl 3, 125–132.
5190
Codesal, J., Regadera, J., Nistal, M., Regadera-‐Sejas, J., Paniagua, R., 1990. Involution of 5191
human fetal Leydig cells. An immunohistochemical, ultrastructural and quantitative 5192
study. J. Anat. 172, 103–114.
5193
Codling, G., Halsall, C., Ahrens, L., Del Vento, S., Wiberg, K., Bergknut, M., Laudon, H., 5194
Ebinghaus, R., 2014. The fate of per-‐ and polyfluoroalkyl substances within a melting 5195
snowpack of a boreal forest. Environ. Pollut. Barking Essex 1987 191, 190–198.
5196
doi:10.1016/j.envpol.2014.04.032 5197
COMMITTEE ON TOXICITY OF CH, EMICALS IN FOOD, CONSUMER, PRODUCTS AND THE 5198
ENVIRONMENT, 2006. COT STATEMENT ON THE TOLE RABLE DAILY INTAKE FOR 5199
PERFLUOROOCTANOIC ACID [WWW Document]. URL 5200
http://cot.food.gov.uk/sites/default/files/cot/cotstatementpfoa200610.pdf (accessed 5201
9.22.14).
5202
COMMITTEE ON TOXICITY OF CHEMICALS IN FOOD,, CONSUMER PRODUCTS AND THE 5203
ENVIRONMENT, n.d. Update statement on the tolerable daily intake for perfluorooctanoic 5204
acid [WWW Document]. URL 5205
http://cot.food.gov.uk/sites/default/files/cot/cotstatementpfoa200902.pdf (accessed 5206
9.21.14).
5207
Conflicts of interest of candidates for the PFOA Risk Assessment Review Panel., n.d.
5208
Consiglio dei Ministri, 2001. Decreto Legislativo 2 febbraio 2001, n. 31 -‐Attuazione della 5209
direttiva 98/83/CE relativa alla qualita’ delle acque destinate al consumo umano" [WWW 5210
Document]. URL http://www.camera.it/parlam/leggi/deleghe/01031dl.htm (accessed 5211
9.21.14).
5212
Consonni, D., Straif, K., Symons, J.M., Tomenson, J.A., van Amelsvoort, L.G.P.M., 5213
Sleeuwenhoek, A., Cherrie, J.W., Bonetti, P., Colombo, I., Farrar, D.G., Bertazzi, P.A., 2013.
5214
Cancer risk among tetrafluoroethylene synthesis and polymerization workers. Am. J.
5215
Epidemiol. 178, 350–358. doi:10.1093/aje/kws588 5216
Contaminazione acque, l’appello dei medici: screening immediato della popolazione » 5217
VicenzaPiù [WWW Document], n.d. URL 5218
http://www.vicenzapiu.com/leggi/contaminazione-‐acque-‐lappello-‐dei-‐medici-‐screening-‐
5219
immediato-‐della-‐popolazione (accessed 8.23.14).
5220
Cook, J.C., Murray, S.M., Frame, S.R., Hurtt, M.E., 1992. Induction of Leydig cell adenomas 5221
by ammonium perfluorooctanoate: a possible endocrine-‐related mechanism. Toxicol.
5222
Appl. Pharmacol. 113, 209–217.
5223
Corsini, E., Avogadro, A., Galbiati, V., dell’ Agli, M., Marinovich, M., Galli, C.L., Germolec, 5224
D.R., 2011. In vitro evaluation of the immunotoxic potential of perfluorinated compounds 5225
(PFCs). Toxicol. Appl. Pharmacol. 250, 108–116. doi:10.1016/j.taap.2010.11.004 5226
Corsini, E., Sangiovanni, E., Avogadro, A., Galbiati, V., Viviani, B., Marinovich, M., Galli, C.L., 5227
Dell’Agli, M., Germolec, D.R., 2012. In vitro characterization of the immunotoxic potential 5228
of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 258, 248–255.
5229
doi:10.1016/j.taap.2011.11.004 5230
Corton, J.C., Cunningham, M.L., Hummer, B.T., Lau, C., Meek, B., Peters, J.M., Popp, J.A., 5231
Rhomberg, L., Seed, J., Klaunig, J.E., 2014. Mode of action framework analysis for receptor-‐
5232
mediated toxicity: The peroxisome proliferator-‐activated receptor alpha (PPARα) as a 5233
case study. Crit. Rev. Toxicol. 44, 1–49. doi:10.3109/10408444.2013.835784 5234
Costa, G., Sartori, S., Consonni, D., 2009. Thirty years of medical surveillance in 5235
perfluooctanoic acid production workers. J. Occup. Environ. Med. Am. Coll. Occup.
5236
Environ. Med. 51, 364–372. doi:10.1097/JOM.0b013e3181965d80 5237
Crist, B.L., Alekel, D.L., Ritland, L.M., Hanson, L.N., Genschel, U., Reddy, M.B., 2009.
5238
Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal 5239
women. J. Womens Health 2002 18, 795–801. doi:10.1089/jwh.2008.0988 5240
Cui, L., Liao, C., Zhou, Q., Xia, T., Yun, Z., Jiang, G., 2010. Excretion of PFOA and PFOS in 5241
male rats during a subchronic exposure. Arch. Environ. Contam. Toxicol. 58, 205–213.
5242
doi:10.1007/s00244-‐009-‐9336-‐5 5243
Cui, L., Zhou, Q., Liao, C., Fu, J., Jiang, G., 2009. Studies on the toxicological effects of PFOA 5244
and PFOS on rats using histological observation and chemical analysis. Arch. Environ.
5245
Contam. Toxicol. 56, 338–349. doi:10.1007/s00244-‐008-‐9194-‐6 5246
Current Restriction intentions -‐ ECHA [WWW Document], n.d. URL 5247
http://echa.europa.eu/registry-‐of-‐current-‐restriction-‐proposal-‐intentions/-‐
5248
/substance/5524/search/+/term (accessed 9.8.14).
5249
Dankers, A.C.A., Roelofs, M.J.E., Piersma, A.H., Sweep, F.C.G.J., Russel, F.G.M., van den Berg, 5250
M., van Duursen, M.B.M., Masereeuw, R., 2013. Endocrine disruptors differentially target 5251
ATP-‐binding cassette transporters in the blood-‐testis barrier and affect Leydig cell 5252
testosterone secretion in vitro. Toxicol. Sci. Off. J. Soc. Toxicol. 136, 382–391.
5253
doi:10.1093/toxsci/kft198 5254
Davis, K.L., Aucoin, M.D., Larsen, B.S., Kaiser, M.A., Hartten, A.S., 2007. Transport of 5255
ammonium perfluorooctanoate in environmental media near a fluoropolymer 5256
manufacturing facility. Chemosphere 67, 2011–2019.
5257
doi:10.1016/j.chemosphere.2006.11.049 5258
De Boo, H.A., Harding, J.E., 2006. The developmental origins of adult disease (Barker) 5259
hypothesis. Aust. N. Z. J. Obstet. Gynaecol. 46, 4–14. doi:10.1111/j.1479-‐
5260
828X.2006.00506.x 5261
De Kleijn, M.J.J., van der Schouw, Y.T., Verbeek, A.L.M., Peeters, P.H.M., Banga, J.-‐D., van der 5262
Graaf, Y., 2002. Endogenous estrogen exposure and cardiovascular mortality risk in 5263
postmenopausal women. Am. J. Epidemiol. 155, 339–345.
5264
Delerive, P., Fruchart, J.C., Staels, B., 2001. Peroxisome proliferator-‐activated receptors in 5265
inflammation control. J. Endocrinol. 169, 453–459. doi:10.1677/joe.0.1690453 5266
Deliberazione della Giunta Regionale n. 168 del 20 febbraio 2014 Pianificazione delle 5267
attività a tutela della salute dei soggetti esposti alla presenza di sostanze 5268
perfluoroalchiliche (PFAS) nelle acque potabili. [WWW Document], n.d. URL 5269
http://bur.regione.veneto.it/BurvServices/pubblica/DettaglioDgr.aspx?id=269219 5270
(accessed 8.23.14).
5271
Deliberazione della Giunta Regionale n. 618 del 29 aprile 2014 Approvazione di “Primi 5272
indirizzi operativi per l’utilizzo dei pozzi privati ai Comuni delle Province interessate dalla 5273
presenza di sostanze perfluoroalchiliche (PFASs) nelle acque destinate al consumo 5274
umano.” [WWW Document], n.d. URL 5275
http://bur.regione.veneto.it/BurvServices/Pubblica/DettaglioDgr.aspx?id=273825 5276
(accessed 8.23.14).
5277
Deliberazione della Giunta Regionale n. 764 del 27 maggio 2014 Approvazione 5278
dell’Accordo di collaborazione tra la Regione del Veneto e l’Istituto Superiore di Sanità 5279
(ISS) finalizzato al “Supporto tecnico scientifico, analitico e consultivo per l’analisi di 5280
rischio correlato alla contaminazione da PFAS di matrici ambientali e filiera idro-‐potabile 5281
in talune circostanze territoriali, e potenziale trasferimento di PFAS alla filiera alimentare 5282
e allo studio di biomonitoraggio.” [WWW Document], n.d. URL 5283
http://bur.regione.veneto.it/BurvServices/pubblica/DettaglioDgr.aspx?id=275287 5284
(accessed 8.23.14).
5285
Denys, S., Fraize-‐Frontier, S., Moussa, O., Bizec, B.L., Veyrand, B., Volatier, J.-‐L., 2014. Is the 5286
fresh water fish consumption a significant determinant of the internal exposure to 5287
perfluoroalkylated substances (PFAS)? Toxicol. Lett. doi:10.1016/j.toxlet.2014.07.028 5288
D’Eon, J.C., Crozier, P.W., Furdui, V.I., Reiner, E.J., Libelo, E.L., Mabury, S.A., 2009.
5289
Observation of a commercial fluorinated material, the polyfluoroalkyl phosphoric acid 5290
diesters, in human sera, wastewater treatment plant sludge, and paper fibers. Environ.
5291
Sci. Technol. 43, 4589–4594.
5292
Dewitt, J.C., Copeland, C.B., Strynar, M.J., Luebke, R.W., 2008. Perfluorooctanoic acid-‐
5293
induced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ.
5294
Health Perspect. 116, 644–650. doi:10.1289/ehp.10896 5295
DeWitt, J.C., Peden-‐Adams, M.M., Keller, J.M., Germolec, D.R., 2011. Immunotoxicity of 5296
Perfluorinated Compounds: Recent Developments. Toxicol. Pathol. 40, 300–311.
5297
doi:10.1177/0192623311428473 5298
DeWitt, J.C., Shnyra, A., Badr, M.Z., Loveless, S.E., Hoban, D., Frame, S.R., Cunard, R., 5299
Anderson, S.E., Meade, B.J., Peden-‐Adams, M.M., Luebke, R.W., Luster, M.I., 2009.
5300
Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of 5301
peroxisome proliferator-‐activated receptor alpha. Crit. Rev. Toxicol. 39, 76–94.
5302
doi:10.1080/10408440802209804 5303
D’Hollander, W., de Voogt, P., De Coen, W., Bervoets, L., 2010. Perfluorinated substances in 5304
human food and other sources of human exposure. Rev. Environ. Contam. Toxicol. 208, 5305
179–215. doi:10.1007/978-‐1-‐4419-‐6880-‐7_4 5306
Diderich, M.B., n.d. (Organization for Economic Co-‐operation and Develop-‐ ment), 2002.
5307
Co-‐operation on existing chemicals. Hazard asses-‐ sment of perfluorooctane sulfonate 5308
(PFOS) and its salts. ENV/JM/RD(2002)17/FINAL, Paris.
5309
Dietert, R.R., 2008. Developmental immunotoxicology (DIT): windows of vulnerability, 5310
immune dysfunction and safety assessment. J. Immunotoxicol. 5, 401–412.
5311
doi:10.1080/15476910802483324 5312
DIRETTIVA 2006/122/CE DEL PARLAMENTO EUROPEO E DEL CONSIGLIO [WWW 5313
Document], 2006. URL http://eur-‐
5314
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:372:0032:0034:it:PDF (accessed 5315
7.26.14).
5316
Dirinck, E.L., Dirtu, A.C., Govindan, M., Covaci, A., Van Gaal, L.F., Jorens, P.G., 2014.
5317
Exposure to persistent organic pollutants: relationship with abnormal glucose 5318
metabolism and visceral adiposity. Diabetes Care 37, 1951–1958. doi:10.2337/dc13-‐2329 5319
Dong, G.-‐H., Tung, K.-‐Y., Tsai, C.-‐H., Liu, M.-‐M., Wang, D., Liu, W., Jin, Y.-‐H., Hsieh, W.-‐S., Lee, 5320
Y.L., Chen, P.-‐C., 2013. Serum polyfluoroalkyl concentrations, asthma outcomes, and 5321
immunological markers in a case-‐control study of Taiwanese children. Environ. Health 5322
Perspect. 121, 507–513, 513e1–8. doi:10.1289/ehp.1205351 5323
Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to 5324
Perfluorooctanoic Acid and Its Salts. Office of Pollution Prevention and Toxics., n.d.
5325
Drinking Water Commission, (Trinkwasserkommission), 2006. Provisional evaluation of 5326
PFT in drinking water with the guide sub-‐ stances perfluorooctanoic acid (PFO A) and 5327
perfluorooctane sulfonate (PFOS) as examples [WWW Document]. URL 5328
http://prevenzione.ulss20.verona.it/docs/Sian/IgieneNutrizione/Acque/Pfas/pft-‐in-‐
5329
drinking-‐water.pdf (accessed 9.13.14).
5330
ECHA, n.d.
5331
Eichenwald, E.C., Stark, A.R., 2008. Management and outcomes of very low birth weight. N.
5332
Engl. J. Med. 358, 1700–1711. doi:10.1056/NEJMra0707601 5333
Elangbam, C.S., Tyler, R.D., Lightfoot, R.M., 2001. Peroxisome Proliferator-‐activated 5334
Receptors in Atherosclerosis and Inflammation—An Update. Toxicol. Pathol. 29, 224–231.
5335
doi:10.1080/019262301317052495 5336
Elcombe, C.R., Elcombe, B.M., Foster, J.R., Chang, S.-‐C., Ehresman, D.J., Butenhoff, J.L., 2012.
5337
Hepatocellular hypertrophy and cell proliferation in Sprague-‐Dawley rats from dietary 5338
exposure to potassium perfluorooctanesulfonate results from increased expression of 5339
xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology 293, 16–29.
5340
doi:10.1016/j.tox.2011.12.014 5341
Elcombe, C.R., Elcombe, B.M., Foster, J.R., Farrar, D.G., Jung, R., Chang, S.-‐C., Kennedy, G.L., 5342
Butenhoff, J.L., 2010. Hepatocellular hypertrophy and cell proliferation in Sprague-‐Dawley 5343
rats following dietary exposure to ammonium perfluorooctanoate occurs through 5344
increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch.
5345
Toxicol. 84, 787–798. doi:10.1007/s00204-‐010-‐0572-‐2 5346
Elcombe, C.R., Peffer, R.C., Wolf, D.C., Bailey, J., Bars, R., Bell, D., Cattley, R.C., Ferguson, S.S., 5347
Geter, D., Goetz, A., Goodman, J.I., Hester, S., Jacobs, A., Omiecinski, C.J., Schoeny, R., Xie, W., 5348
Lake, B.G., 2014. Mode of action and human relevance analysis for nuclear receptor-‐
5349
mediated liver toxicity: A case study with phenobarbital as a model constitutive 5350
androstane receptor (CAR) activator. Crit. Rev. Toxicol. 44, 64–82.
5351
doi:10.3109/10408444.2013.835786 5352
Emmett, E.A., Zhang, H., Shofer, F.S., Freeman, D., Rodway, N.V., Desai, C., Shaw, L.M., 2006.
5353
Community exposure to perfluorooctanoate: relationships between serum levels and 5354
certain health parameters. J. Occup. Environ. Med. Am. Coll. Occup. Environ. Med. 48, 771–
5355
779. doi:10.1097/01.jom.0000233380.13087.37 5356
Entringer, S., Buss, C., Wadhwa, P.D., 2010. Prenatal stress and developmental 5357
programming of human health and disease risk: concepts and integration of empirical 5358
findings. Curr. Opin. Endocrinol. Diabetes Obes. 17, 507–516.
5359
doi:10.1097/MED.0b013e3283405921 5360
ENVIRONMENTAL AND HEALTH ASSESSMENT OF PERFLUOROOCTANE SULFONIC ACID 5361
AND ITS SALTS, n.d.
5362
Environmental and Occupational Health Program, Division of Environmental Health, 5363
Maine Center f, or Disease Control & Prevention, Department of Health and Human 5364
Services, 2014. Maximum Exposure Guideline for Perfluorooctanoic Acid in Drinking 5365
Water [WWW Document]. URL http://www.maine.gov/dhhs/mecdc/environmental-‐
5366
health/eohp/wells/documents/pfoameg.pdf (accessed 9.9.14).
5367
Environment Canada Health Canada, 2012. Draft Screening Assessment for the Challenge 5368
[WWW Document]. URL http://www.ec.gc.ca/ese-‐ees/370AB133-‐3972-‐454F-‐A03A-‐
5369
F18890B58277/PFOA_EN.pdf (accessed 7.27.14).
5370
ENVPFC -‐ OECD [WWW Document], n.d. URL http://www.oecd.org/ehs/pfc/ (accessed 5371
8.12.14).
5372
enzucciu, P. da, n.d. Enzucciu: Le sostanze perfluoroalchiliche sono cancerogene in 5373
America ma in Veneto sono innocue.
5374
EPA, U., n.d. DuPont Agrees to Lower Limit of PFOA in Drinking Water DuPont 5375
Washington Works (March 2009) -‐ dupont-‐fs-‐200903.pdf [WWW Document]. URL 5376
http://www.epa.gov/r5water/gwdw/dupont/pdfs/dupont-‐fs-‐200903.pdf (accessed 5377
2.13.15a).
5378
EPA, U., n.d. II. Benchmark Dose (BMD) Methodology [WWW Document]. URL 5379
http://www.epa.gov/ncea/bmds/bmds_training/methodology/intro.htm#BMD 5380
(accessed 9.17.14b).
5381
Eriksen, K.T., Raaschou-‐Nielsen, O., McLaughlin, J.K., Lipworth, L., Tjønneland, A., Overvad, 5382
K., Sørensen, M., 2013. Association between Plasma PFOA and PFOS Levels and Total 5383
Cholesterol in a Middle-‐Aged Danish Population. PLoS ONE 8, e56969.
5384
doi:10.1371/journal.pone.0056969 5385
Eriksen, K.T., Sørensen, M., McLaughlin, J.K., Lipworth, L., Tjønneland, A., Overvad, K., 5386
Raaschou-‐Nielsen, O., 2009. Perfluorooctanoate and Perfluorooctanesulfonate Plasma 5387
Levels and Risk of Cancer in the General Danish Population. J. Natl. Cancer Inst. 101, 605–
5388
609. doi:10.1093/jnci/djp041 5389
EUROPEA, I.C.D., 1999. DIRETTIVA 98/83/CE DEL CONSIGLIO del 3 novembre 1998 5390
concernente la qualità delle acque destinate al consumo umano. Gazzetta Uff. L 330, 5.
5391
European Commission -‐ Enterprise and Industry -‐ TRIS [WWW Document], 2010. URL 5392
http://ec.europa.eu/enterprise/tris/pisa/app/search/index.cfm?fuseaction=getdraft&in 5393
um=1613083 (accessed 7.27.14).
5394
Fair, P.A., Driscoll, E., Mollenhauer, M.A.M., Bradshaw, S.G., Yun, S.H., Kannan, K., Bossart, 5395
G.D., Keil, D.E., Peden-‐Adams, M.M., 2011. Effects of environmentally-‐relevant levels of 5396
perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 5397
mice. J. Immunotoxicol. 8, 17–29. doi:10.3109/1547691X.2010.527868 5398
Falk, S., Failing, K., Georgii, S., Brunn, H., Stahl, T., 2014. Tissue specific uptake and 5399
elimination of perfluoroalkyl acids (PFAAs) in adult rainbow trout (Oncorhynchus 5400
mykiss) after dietary exposure. Chemosphere. doi:10.1016/j.chemosphere.2014.06.061 5401
Fang, X., Zhang, L., Feng, Y., Zhao, Y., Dai, J., 2008. Immunotoxic effects of 5402
perfluorononanoic acid on BALB/c mice. Toxicol. Sci. Off. J. Soc. Toxicol. 105, 312–321.
5403
doi:10.1093/toxsci/kfn127 5404
Fasano, W.J., Kennedy, G.L., Szostek, B., Farrar, D.G., Ward, R.J., Haroun, L., Hinderliter, 5405
P.M., 2005. Penetration of ammonium perfluorooctanoate through rat and human skin in 5406
vitro. Drug Chem. Toxicol. 28, 79–90. doi:10.1081/DCT-‐39707 5407
Fei, C., McLaughlin, J.K., Lipworth, L., Olsen, J., 2009. Maternal levels of perfluorinated 5408
chemicals and subfecundity. Hum. Reprod. Oxf. Engl. 24, 1200–1205.
5409
doi:10.1093/humrep/den490 5410
Fei, C., McLaughlin, J.K., Tarone, R.E., Olsen, J., 2007. Perfluorinated chemicals and fetal 5411
growth: a study within the Danish National Birth Cohort. Environ. Health Perspect. 115, 5412
1677–1682. doi:10.1289/ehp.10506 5413
Fei, C., McLaughlin, J.K., Tarone, R.E., Olsen, J., 2008. Fetal growth indicators and 5414
perfluorinated chemicals: a study in the Danish National Birth Cohort. Am. J. Epidemiol.
5415
168, 66–72. doi:10.1093/aje/kwn095 5416
Fernández Freire, P., Pérez Martin, J.M., Herrero, O., Peropadre, A., de la Peña, E., Hazen, 5417
M.J., 2008. In vitro assessment of the cytotoxic and mutagenic potential of 5418
perfluorooctanoic acid. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 22, 1228–1233.
5419
doi:10.1016/j.tiv.2008.04.004 5420
Ferré, P., 2004. The Biology of Peroxisome Proliferator-‐Activated Receptors Relationship 5421
With Lipid Metabolism and Insulin Sensitivity. Diabetes 53, S43–S50.
5422
doi:10.2337/diabetes.53.2007.S43 5423
Fisher, M., Arbuckle, T.E., Wade, M., Haines, D.A., 2013. Do perfluoroalkyl substances affect 5424
metabolic function and plasma lipids?-‐-‐Analysis of the 2007-‐2009, Canadian Health
metabolic function and plasma lipids?-‐-‐Analysis of the 2007-‐2009, Canadian Health